Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

kristy carr

  • Home
  •  
  • kristy carr



  • Most Read
  • Latest Comments
  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • News

  • Bubs goes full steam ahead with US FDA trials in rising market for infant formula
    Bubs goes full steam ahead with US FDA trials in rising market for infant formula
    • News

  • Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    • News

  • Un-Happy Valley Nutrition: infant formula company collapses as director and CFO walk out
    Un-Happy Valley Nutrition: infant formula company collapses as director and CFO walk out
    • News

  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • News

    Bubs Australia rebounds in China after CEO fiasco, sees USA growth

    Baby formula company Bubs Australia (ASX: BUB) has all but closed the chapter on its financial and legal troubles that underlined most of last year.  In the USA, its weekly scan revenue exceeded $1.5 million per week, with over 24,000 tins sold. The number of tins sold increased by 10k to about 24k compared to

    Read More
    Public
  • Bubs goes full steam ahead with US FDA trials in rising market for infant formula
    • News

    Bubs goes full steam ahead with US FDA trials in rising market for infant formula

    Baby formula and food company Bubs Australia (ASX: BUB) spent a large part of FY23 undertaking reputation management as its dirty laundry was hung for the world to see. Boardroom disputes, miffed shareholders, lawsuits, and a CEO ousting—the Company had to work in overdrive to maintain shareholder confidence. The impact of its decisions can be

    Read More
    Public
  • Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    • News

    Bubs presents its rebound plan after bitter breakup with former CEO and Chairman

    A bitter boardroom spat has left baby formula company Bubs Australia (ASX: BUB) scrambling to undertake serious damage control following a disappointing year, financially, and fruitless attempts at chasing debts created by previous management. In an attempt to calm shareholder unrest, the Company has presented its strategic review to start over. During the three-year period

    Read More
    Public
  • Bubs Australia founder and CEO forced out for alleged failure to comply with board directions
    • News

    Bubs Australia founder and CEO forced out for alleged failure to comply with board directions

    Just a month after Bubs Australia (ASX: BUB) announced that executive chairman Dennis Lin would be removed from the business, the baby milk formula company announced another shake up of its executive line up. Perhaps a foreseeable one, this time founder and CEO Kristy Carr was terminated from her position with immediate effect due to

    Read More
    Public
  • China revenue falls 66% as Bubs reports declining sales
    • News

    China revenue falls 66% as Bubs reports declining sales

    The infant formula market has more than doubled over the past decade. But not all companies have managed to keep up, thus making it a lucrative market for the few that have. Infant formula companies, like Bubs Australia (ASX: BUB), saw it as an opportunity to expand into global markets, even becoming one of the

    Read More
    Public
  • Bubs lodges letter of intent with FDA to become a permanent seller in the USA
    • News

    Bubs lodges letter of intent with FDA to become a permanent seller in the USA

    After a successful entry into the USA during their recent dairy crisis, infant nutrition and dairy specialist Bubs Australia (ASX: BUB) has lodged a letter of intent to continue selling six Bubs Infant Formula products in the country till October 2025 and beyond. The Australian Company is one of only eight infant formula manufacturers globally

    Read More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.